Numerus

Numerus

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Numerus is a specialized biostatistics services firm based in Cambridge, UK, that supports life sciences companies from clinical development through market access. The company leverages a team with deep collective industry experience to offer statistical design, analysis, and reporting for clinical trials, HTA submissions, and real-world data studies. It operates as a service provider rather than a drug developer, helping clients build compelling evidence narratives for regulators and payers. Numerus addresses the critical need for robust statistical evidence in an increasingly complex and data-driven regulatory environment.

AI / Machine LearningDrug Discovery

Technology Platform

Expert biostatistical consultancy leveraging advanced statistical methodologies (e.g., clinical trial simulation, evidence synthesis, real-world data analysis) within a regulatory framework, utilizing tools like SAS and R.

Opportunities

Growing demand for sophisticated statistical support for Health Technology Assessment (HTA) and market access submissions presents a major opportunity.
The increased regulatory acceptance of Real-World Evidence (RWE) opens a new and expanding service line for complex data analysis beyond traditional clinical trials.

Risk Factors

The business is highly dependent on recruiting and retaining specialized statistical talent in a competitive market.
As a niche service provider, it faces competition from large CROs and is susceptible to client concentration risk and potential downturns in biopharma R&D spending.

Competitive Landscape

Numerus competes in a fragmented market including large full-service Contract Research Organizations (CROs) with biostatistics divisions and other specialized statistical consultancies. Its differentiation is based on high-touch, expert-level service and deep regulatory experience, rather than scale or low cost.